Skip to main content
. Author manuscript; available in PMC: 2021 Dec 23.
Published in final edited form as: Eur Respir J. 2018 Apr 19;51(4):1702258. doi: 10.1183/13993003.02258-2017

Table 3.

Analysis of potential treatment of LAM patients based on a method derived from rates of decline in pre-menopausal patients with FEV1 or DLCO > 70 % predicted *

Treated Based on Analytical
Method
Yes No Total
FEV1> 70 % 12 (24.5) 37 (75.5) 49 (100.0)
DLCO> 70 % 11 (24.4) 34 (75.6) 45 (100.0)
*

Columns show the numbers of patients to be treated with mTOR inhibitors when the observed FEV1 and DLCO were lower than the expected values derived from rates of decline in FEV1 and DLCO. Percentages of patients are shown within parenthesis.